Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.65 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221042 | 1.00 | FAAH (0.70) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL5215792 | 1.00 | FAAH (0.70) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL5221933 | 1.00 | FAAH (0.70) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL5223000 | 1.00 | FAAH (0.70) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL2089631 | 1.00 | FAAH (0.70) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL2097878 | 0.98 | GAA (0.69) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL5218010 | 0.95 | GAA (0.64) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL2089628 | 0.87 | FAAH (0.66) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL9885419 | 0.87 | FAAH (0.68) | FAAHGAAL3MBTL1 | |
| SCHEMBL16316826 | 0.87 | FAAH (0.68) | FAAHGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | disclosed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885GAA 517/4885L3MBTL1 2799/4885 |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885GAA 517/4885L3MBTL1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.